PCA3: a molecular urine assay for predicting prostate biopsy outcome. - Wikidata - wikimedia - TriplyDB

PCA3: a molecular urine assay for predicting prostate biopsy outcome.

PCA3: a molecular urine assay for predicting prostate biopsy outcome.

http://www.wikidata.org/entity/Q34754205

about

PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer Immunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate Cancer PSA and beyond: alternative prostate cancer biomarkers Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel Emerging critical role of molecular testing in diagnostic genitourinary pathology Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease Novel biomarkers for prostate cancer including noncoding transcripts.A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery.Comparison of prostate cancer diagnosis in patients receiving unrelated urological and non-urological cancer care.A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France In-depth proteomic analyses of direct expressed prostatic secretions.Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.The Xu's chart for prostate biopsy: a visual presentation of the added value of biomarkers to prostate-specific antigen for estimating detection rates of prostate cancer.Current early diagnostic biomarkers of prostate cancer The use of exome genotyping to predict pathological Gleason score upgrade after radical prostatectomy in low-risk prostate cancer patients Proteomics in prostate cancer biomarker discovery.The novel prostate cancer antigen 3 (PCA3) biomarker.Novel diagnostic biomarkers for prostate cancer.Can urinary PCA3 supplement PSA in the early detection of prostate cancer?DNA methylation profiling reveals novel diagnostic biomarkers in renal cell carcinoma.A genetic-based approach to personalized prostate cancer screening and treatment.Prostate cancer screening and determining the appropriate prostate-specific antigen cutoff values.Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer.Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy.Clinical evaluation of prostate cancer gene 3 score in diagnosis among Chinese men with prostate cancer and benign prostatic hyperplasia.Comparative Study of Extracellular Vesicles from the Urine of Healthy Individuals and Prostate Cancer Patients.RNA biomarkers to facilitate the identification of aggressive prostate cancer Prostate cancer markers: An update.Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine.Joint modeling, covariate adjustment, and interaction: contrasting notions in risk prediction models and risk prediction performance Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis.Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study.Systematic, evidence-based discovery of biomarkers at the NCI.Imaging and Markers as Novel Diagnostic Tools in Detecting Insignificant Prostate Cancer: A Critical Overview The present and future of prostate cancer urine biomarkers.Divorcing diagnosis from treatment: contemporary management of low-risk prostate cancer.Evaluating and comparing biomarkers with respect to the area under the receiver operating characteristics curve in two-phase case-control studies.Long noncoding RNAs in prostate cancer: overview and clinical implications.

P2860

Q26752933-A2BEF9FC-C730-48BF-8986-23375A750A1D Q26767044-6EC5FD0F-2EC7-4954-8F63-F3B126B196BA Q26770646-78B2CD41-F126-4C26-A9DC-8C31BF3EA378 Q27001399-241F9B3C-6305-4FF0-B232-B2559A09EB7E Q27021371-4FBB7B46-23AA-4A3F-85CB-843493DFC912 Q33449075-B3045A48-E0A0-4397-BE91-7F803697078F Q33515231-8CCBA018-8782-41E8-81A1-4724C484884C Q33558289-C816B8F6-9924-4CD2-B4D7-7972840722AF Q33567004-79EAD314-0D99-4C50-8826-753423123A05 Q33581483-4D41E7DA-5286-4A19-BCEB-B54E2E9327D5 Q33751970-C224C09B-665D-42F8-BBE3-8DB8DBC083C4 Q33849273-ABE3FB9C-FEF0-4969-BF6A-0EC45423F2E9 Q33897630-808294D2-7D8E-4EFF-AB14-F9B543BED1FE Q33922385-A1BAAFFA-2F24-48D2-8611-401451341686 Q33922390-012EB47A-D2C9-4EC2-9FE3-846E6937413A Q34004995-F5E69A61-35DB-42E9-BE65-1A70CD491D16 Q34096086-478E00DD-C4D6-4DCE-95FA-577371BDE023 Q34156075-34108CF8-4691-41F0-A912-8814973F47B5 Q34231678-8A09DDD5-3745-4D1D-A5EA-ADB9CDD86B21 Q34692263-E3465C6D-9D9D-4883-88B4-5D91419AB825 Q34694198-6EE353E9-F56D-4826-A6B9-222891310D20 Q34802764-A33E5CBF-C275-412A-83FD-D64A5843D8B5 Q35022732-E0810ADF-9C82-4005-B621-08D6AB3A81E8 Q35251546-F67C2915-9D58-4732-A13D-329B6483BB30 Q35632848-219539F8-BC57-473C-BDD0-CCA18D064DDE Q35771276-C0BF88F1-A4A0-4E86-AAF7-0413D84E2539 Q35858216-764E005F-51D7-48EB-9EA8-F37C6DECD6B7 Q36053185-BD8F88CE-709B-4873-9EA1-E16A2B6540FA Q36260364-0B940581-455A-4E66-938E-842727B9DE94 Q36640109-BB83E264-8C97-4A34-A0F7-1452797AFC07 Q36811800-68E9A28E-EF04-4A87-A01F-7B96FCD67522 Q36862689-E6D85E36-E498-4706-93F0-25D45AB3358C Q36886346-F25666EE-2D01-4C01-AC77-BFFC86721521 Q36907574-D43CF507-7641-47FC-9513-EC353BFDAD30 Q36922015-1CFE11E3-776B-4158-BBB9-9DEA68B3217E Q36979944-750A8DB1-7D27-4E5D-A6FB-1355C083074C Q37007392-E2D198A5-122E-481F-869B-205003AAB838 Q37025434-4635877A-4640-4DC9-A18A-7819E7303B99 Q37025741-FEE870FD-3BF5-445B-B960-F3D9D4EC3AE1 Q37113177-BFB38007-9BBA-4641-80EF-C542BEECE8E5

P2860

PCA3: a molecular urine assay for predicting prostate biopsy outcome.

http://www.wikidata.org/entity/Q34754205

description

2008 nî lūn-bûn

@nan

2008 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մարտին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

PCA3: a molecular urine assay for predicting prostate biopsy outcome.

@ast

PCA3: a molecular urine assay for predicting prostate biopsy outcome.

@en

PCA3: a molecular urine assay for predicting prostate biopsy outcome.

@nl

type

label

PCA3: a molecular urine assay for predicting prostate biopsy outcome.

@ast

PCA3: a molecular urine assay for predicting prostate biopsy outcome.

@en

PCA3: a molecular urine assay for predicting prostate biopsy outcome.

@nl

prefLabel

PCA3: a molecular urine assay for predicting prostate biopsy outcome.

@ast

PCA3: a molecular urine assay for predicting prostate biopsy outcome.

@en

PCA3: a molecular urine assay for predicting prostate biopsy outcome.

@nl

P1433

Q34754205-5AD088FD-5D40-4141-9518-4F045EA5B56D

P1476

Q34754205-A6201065-A911-4FC5-A85F-0D2A0948194A

P2093

Q34754205-1E0AE81A-B32C-4C98-A3EC-D7E1C3A10964

Q34754205-2B2861BA-3476-4DE6-8F7C-90A0D5CF59B8

Q34754205-2E84B51F-CC23-4D04-97EE-54812A8DE4C0

Q34754205-547A5E8B-6D77-4784-8B86-353648FACB2B

Q34754205-7B4B6A87-6EE8-4BF6-B3CF-BCA3A04B1893

Q34754205-ACC8C7FB-2C26-4934-AC62-CF4B4A422692

Q34754205-BE3F4B35-7B27-4EAD-A6B2-D9614B19ED38

Q34754205-C226903D-A279-4A2D-8F4F-CC719F7C5B66

Q34754205-DA28A0FB-951A-485A-89B5-0DECD45E1374

Q34754205-EC631698-6EFC-489D-85E8-8331D1F2D369

P304

Q34754205-1F7AAE2A-2D69-4124-8734-7C22760E9A48

P31

Q34754205-8E0CA52F-2653-4B7B-876B-12145C8323B7

P356

Q34754205-01103095-7798-4C3C-9AE1-F0EDF2D804D9

P407

Q34754205-E5BAC280-7A1D-468B-942D-A65FBFAB61BE

P433

Q34754205-D702CEAE-1EAB-4D6D-9BF2-7759DAF07E8B

P478

Q34754205-C0502AD0-A09B-4323-BABC-D3424173B28E

P50

Q34754205-0552E077-A109-4BC1-A9B1-8C850AA892AC

P577

Q34754205-8AC85E37-F355-4A73-89E8-B1F6ED5A1203

P698

Q34754205-75630B1E-B68D-4795-B2BB-D56430293F1E

P921

Q34754205-D3B36798-FC2E-4B20-8106-CAF4ABC21214

P356

J.JURO.2007.11.038

P1433

The Journal of Urology

P1476

PCA3: a molecular urine assay for predicting prostate biopsy outcome.

@en

P2093

Amy Blase

http://www.w3.org/2001/XMLSchema#string

Harry Rittenhouse

http://www.w3.org/2001/XMLSchema#string

Ina L Deras

http://www.w3.org/2001/XMLSchema#string

Jack Groskopf

http://www.w3.org/2001/XMLSchema#string

John R Day

http://www.w3.org/2001/XMLSchema#string

Leonard S Marks

http://www.w3.org/2001/XMLSchema#string

Seongjoon Koo

http://www.w3.org/2001/XMLSchema#string

Sheila M J Aubin

http://www.w3.org/2001/XMLSchema#string

William J Ellis

http://www.w3.org/2001/XMLSchema#string

Yves Fradet

http://www.w3.org/2001/XMLSchema#string

P304

1587-1592

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JURO.2007.11.038

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

179

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18295257

http://www.w3.org/2001/XMLSchema#string

P921